Abstract: The present invention relates to the preparation of a liquid fermentate of Sanghuangporus or an extract of Sanghuangporus, compounds identified from the liquid fermentate or the extract, and their novel activity.

Abstract: The present invention relates to a monascuspurpurone compound of formula (I): or a pharmaceutically acceptable derivative thereof as described in the specification, the process for preparation of the same, and the composition comprising the same. The uses of a monascuspurpurone compound for promoting adipocyte differentiation, for increasing the activity of PPAR? and/or C/EBP?, for lowering blood glucose, for preventing and/or treating a disease or disorder related to insulin resistance, and for preventing and/or treating metabolic syndrome or its complications are also provided.

Abstract: The present invention relates to a novel monascuspurpurone compound of formula (I): or a pharmaceutically acceptable derivative thereof as described in the specification, the process for preparation of the same, and the composition comprising the same. The uses to of a monascuspurpurone compound for promoting adipocyte differentiation, for increasing the activity of PPAR? and/or C/EBP?, for lowering blood glucose, for preventing and/or treating a disease or disorder related to insulin resistance, and for preventing and/or treating metabolic syndrome or its complications are also provided.

Abstract: A method for inhibiting xanthine oxidase and for reducing uric acid levels using a beta-carboline alkaloid compound of formula (I), wherein R1 is selected from the group consisting of a carboxyl group, a carboxylate group, a carboxamide group and hydrogen, and R2 is selected from the group consisting of —CH2COOCH3, a methoxy group, hydrogen and a methyl group. Also disclosed is a method for monitoring xanthine oxidase inhibiting activity level.

Abstract: The present invention relates to novel pyridine alkaloid compounds of formula (I): or a pharmaceutically acceptable derivative thereof as described in the specification, the process for the preparation of the same, and the composition comprising the same. The uses of a pyridine compound for increasing the activity of PPAR?, for the prevention and/or treatment of a disease or disorder related to insulin resistance, and for the prevention and/or treatment of metabolic syndrome or its complication are also provided. The invention also provides extracts of red yeast-fermented products and their uses for prevention and/or treatment of a disease or disorder related to insulin resistance, such as metabolic syndrome.

Abstract: The present invention relates to a novel monascuspurpurone compound of formula (I): or a pharmaceutically acceptable derivative thereof as described in the specification, the process for preparation of the same, and the composition comprising the same. The uses of a monascuspurpurone compound for promoting adipocyte differentiation, for increasing the activity of PPAR? and/or C/EBP?, for lowering blood glucose, for preventing and/or treating a disease or disorder related to insulin resistance, and for preventing and/or treating metabolic syndrome or its complications are also provided.

Abstract: The present invention concerns the uses of an azaphilone compound of formula (I): formula (I): or a pharmaceutically acceptable derivative thereof as described in the specification for modulation of the activity of a nuclear hormone receptor and for prevention and/or treatment of a disease or disorder related to nuclear hormone receptor activity.

Abstract: The present invention relates to a novel monascuspurpurone compound of formula (I): or a pharmaceutically acceptable derivative thereof as described in the specification, the process for preparation of the same, and the composition comprising the same. The uses to of a monascuspurpurone compound for promoting adipocyte differentiation, for increasing the activity of PPAR? and/or C/EBP?, for lowering blood glucose, for preventing and/or treating a disease or disorder related to insulin resistance, and for preventing and/or treating metabolic syndrome or its complications are also provided.

Abstract: The present invention relates to a novel monascuspurpurone compound of formula (I): or a pharmaceutically acceptable derivative thereof as described in the specification, the process for preparation of the same, and the composition comprising the same. The uses of a monascuspurpurone compound for promoting adipocyte differentiation, for increasing the activity of PPAR? and/or C/EBP?, for lowering blood glucose, for preventing and/or treating a disease or disorder related to insulin resistance, and for preventing and/or treating metabolic syndrome or its complications are also provided.

Abstract: The present invention relates to novel pyridine alkaloid compounds of formula (I): or a pharmaceutically acceptable derivative thereof as described in the specification, the process for the preparation of the same, and the composition comprising the same. The uses of a pyridine compound for increasing the activity of PPAR?, for the prevention and/or treatment of a disease or disorder related to insulin resistance, and for the prevention and/or treatment of metabolic syndrome or its complication are also provided. The invention also provides extracts of red yeast-fermented products and their uses for prevention and/or treatment of a disease or disorder related to insulin resistance, such as metabolic syndrome.

Abstract: The present invention concerns the uses of an azaphilone compound of formula (I): formula (I): or a pharmaceutically acceptable derivative thereof as described in the specification for modulation of the activity of a nuclear hormone receptor and for prevention and/or treatment of a disease or disorder related to nuclear hormone receptor activity.